enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
8.07
-0.15 (-1.82%)
At close: Dec 5, 2025, 4:00 PM EST
8.06
-0.01 (-0.12%)
After-hours: Dec 5, 2025, 7:03 PM EST
enGene Holdings Employees
As of October 31, 2024, enGene Holdings had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 24 or 72.73% compared to the previous year.
Employees
57
Change (1Y)
24
Growth (1Y)
72.73%
Revenue / Employee
n/a
Profits / Employee
-$1,661,772
Market Cap
539.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 57 | 24 | 72.73% |
| Oct 31, 2023 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENGN News
- 3 days ago - enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness - Business Wire
- 10 days ago - enGene to Present at the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 23 days ago - enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants - Business Wire
- 23 days ago - enGene Announces Proposed Public Offering of Common Shares - Business Wire
- 23 days ago - enGene Holdings: Still A Buy After A Massive Surge - Seeking Alpha
- 24 days ago - enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript - Seeking Alpha
- 24 days ago - EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial - Benzinga
- 24 days ago - Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months - Business Wire